Grifols (GIFLF) Cash from Financing Activities (2010 - 2025)
Grifols' (GIFLF) quarterly Cash from Financing Activities came in at -$615.8 million in Q4 2025, up 57.6% on a YoY basis from -$390.7 million in Q4 2024, and up 57.6% quarter-over-quarter from -$1.5 billion in Q4 2024.
Powered by 
Analysis
Grifols (GIFLF) Cash from Financing Activities (2010 - 2025) Analysis & Trends
Grifols (GIFLF) has reported Cash from Financing Activities for 14 consecutive years, with -$615.8 million the latest figure, recorded in Q4 2025.
- For the quarter ending Q4 2025, Cash from Financing Activities rose 57.6% year-over-year to -$615.8 million; the trailing twelve-month figure through Dec 2025 stood at -$2.4 billion (down 17.47% YoY), and the FY2025 full-year result was -$597.7 million, up 58.84% from the prior year.
- Cash from Financing Activities advanced to -$615.8 million in Q4 2025 per GIFLF's latest filing, from -$1.5 billion in the prior quarter.
- Across five years, Cash from Financing Activities topped out at -$168.2 million in Q4 2022 and bottomed at -$1.5 billion in Q4 2024.
- Historically, Cash from Financing Activities has averaged -$745.4 million across 3 years, with a median of -$615.8 million in 2025.
- The widest YoY moves for Cash from Financing Activities: up 57.6% in 2025, down 57.6% in 2025.
- Over 3 years, Cash from Financing Activities stood at -$168.2 million in 2022, then sank by 763.19% to -$1.5 billion in 2024, then surged by 57.6% to -$615.8 million in 2025.
- According to Business Quant data, Cash from Financing Activities over the past three periods registered -$615.8 million, -$1.5 billion, and -$168.2 million for Q4 2025, Q4 2024, and Q4 2022 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 203.97 Bn | 189.99 Bn | 7.24 Bn | -1.48 Bn |
| 2 | Gilead Sciences | 178.74 Bn | 175.56 Bn | 6.22 Bn | 2.34 Bn |
| 3 | Vertex Pharmaceuticals | 130.73 Bn | 122.88 Bn | 2.84 Bn | -426.70 Mn |
| 4 | Regeneron Pharmaceuticals | 80.42 Bn | 72.42 Bn | 3.93 Bn | -1.22 Bn |
| 5 | Argenx Se | 60.40 Bn | 55.21 Bn | 1.37 Bn | - |
| 6 | Moderna | 57.65 Bn | 52.52 Bn | 52.00 Mn | 14.00 Mn |
| 7 | Alnylam Pharmaceuticals | 33.37 Bn | 30.07 Bn | 992.69 Mn | 36.24 Mn |
| 8 | Biogen | 32.15 Bn | 30.86 Bn | 1.96 Bn | 1.30 Bn |
| 9 | Roivant Sciences | 29.58 Bn | 29.58 Bn | 1.16 Mn | -181.51 Mn |
| 10 | Grifols | 7.54 Bn | 9.09 Bn | 3.33 Bn | -615.78 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2025 | -615.78 Mn |
| Dec 31, 2024 | -1.45 Bn |
| Dec 31, 2022 | -168.24 Mn |
| Mar 31, 2020 | -121.48 Mn |
| Dec 31, 2019 | -265.22 Mn |
| Mar 31, 2019 | -62.92 Mn |
| Dec 31, 2018 | 93.43 Mn |
| Jun 30, 2018 | -207.36 Mn |
| Mar 31, 2018 | 15.58 Mn |
| Dec 31, 2017 | 1.76 Bn |
| Jun 30, 2017 | -97.45 Mn |
| Mar 31, 2017 | 1.67 Bn |
| Dec 31, 2016 | -146.57 Mn |
| Sep 30, 2016 | -35.48 Mn |
| Dec 31, 2015 | -326.65 Mn |
| Sep 30, 2015 | -8.13 Mn |
| Jun 30, 2015 | 207.83 Mn |
| Mar 31, 2015 | -46.07 Mn |
| Dec 31, 2014 | -121.23 Mn |
| Sep 30, 2014 | 1.24 Bn |